Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$135.99 USD
-1.77 (-1.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $135.92 -0.07 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NBIX 135.99 -1.77(-1.28%)
Will NBIX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for NBIX
Promising Outlook for Neurocrine’s NBI-‘845 in MDD Market Based on Strong Phase 2 Results and Competitive Positioning
Buy Rating Affirmed for Neurocrine on Promising Phase 2 SAVITRI Study Results
Maintaining Hold on Neurocrine Amid Promising Yet Uncertain Clinical Developments
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Neurocrine Biosciences upgraded at Wells Fargo on pipeline